For help on how to get the results you want, see our search tips.
8 results
Categories
Human Remove Human filter
-
List item
Summary of opinion: Livogiva
teriparatide, opinion date: 25/06/2020, Positive, Last updated: 26/06/2020 -
List item
Summary of opinion: Qutavina
teriparatide, opinion date: 25/06/2020, Positive, Last updated: 26/06/2020 -
List item
Summary of opinion: Crysvita
burosumab, opinion date: 23/07/2020, Positive, Last updated: 24/07/2020 -
List item
Summary of opinion: Deltyba
delamanid, opinion date: 17/09/2020, Positive, Last updated: 18/09/2020 -
List item
Summary of opinion: Nyvepria
pegfilgrastim, opinion date: 17/09/2020, Positive, Last updated: 18/09/2020 -
List item
Referral: Lartruvo
olaratumab, associated names: Lartruvo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/01/2019, EC decision date: 19/07/2019, Last updated: 22/08/2019 -
List item
Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin)
Active substance: polatuzumab vedotin, DHPC type: Quality defect, Last updated: 04/05/2020 -
List item
Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa
Active substance: andexanet alfa, DHPC type: Safety signal, Last updated: 17/06/2020